Cost-Effectiveness and Burden of Disease for Adjuvanted Quadrivalent Influenza Vaccines Compared to High-Dose Quadrivalent Influenza Vaccines in Elderly Patients in Spain
Open Access
Abstract
Influenza is a contagious respiratory disease that causes severe illness and death, particularly in elderly populations. Two enhanced formulations of quadrivalent influenza vaccine (QIV) are available in Spain. Adjuvanted QIV (aQIV) is available for those aged 65+ and high-dose QIV (HD-QIV) for those aged 60+. In this study, we used a health economic model to assess the costs and outcomes associated with using aQIV or HD-QIV in subjects aged 65+. Using aQIV instead of HD-QIV to vaccinate an estimated 5,126,343 elderly people results in reductions of 5405 symptomatic cases, 760 primary care visits, 171 emergency room visits, 442 hospitalizations, and 26 deaths in Spain each year. Life-years (LYs) and quality-adjusted LYs (QALYs) increases by 260 and 206, respectively, each year. Savings from a direct medical payer perspective are EUR 63.6 million, driven by the lower aQIV vaccine price and a minor advantage in effectiveness. From a societal perspective, savings increase to EUR 64.2 million. Results are supported by scenario and sensitivity analyses. When vaccine prices are assumed equal, aQIV remains dominant compared to HD-QIV. Potential savings are estimated at over EUR 61 million in vaccine costs alone. Therefore, aQIV provides a highly cost-effective alternative to HD-QIV for people aged 65+ in Spain.Keywords
Funding Information
- Seqirus (United States) (N/A)
This publication has 33 references indexed in Scilit:
- Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission ModelPharmacoEconomics, 2016
- Impact of quadrivalent influenza vaccine on public health and influenza-related costs in AustraliaBMC Public Health, 2016
- Cost–effectiveness analysis of quadrivalent influenza vaccine in SpainHuman Vaccines & Immunotherapeutics, 2016
- Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in EuropeHuman Vaccines & Immunotherapeutics, 2016
- An Assessment of the Expected Cost-Effectiveness of Quadrivalent Influenza Vaccines in Ontario, Canada Using a Static ModelPLOS ONE, 2015
- Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older AdultsNew England Journal of Medicine, 2014
- Impact of Influenza on Health-Related Quality of Life among Confirmed (H1N1)2009 PatientsPLOS ONE, 2013
- Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccineVaccine, 2012
- Spanish recommendations on economic evaluation of health technologiesThe European Journal of Health Economics, 2010
- Random-effects model for meta-analysis of clinical trials: An updateContemporary Clinical Trials, 2007